KEYTRUDA vs UNLOXCYT

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. KEYTRUDA and UNLOXCYT are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KEYTRUDA	UNLOXCYT
Rating	70/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	PEMBROLIZUMAB	COSIBELIMAB-IPDL
Manufacturer	Merck Sharp Dohme	Checkpoint Therapeutics Inc
Dosage forms	Injectable	Injectable
Drug class	Programmed Death Receptor-1 Blocking Antibody	—
Boxed warning	None	None
Treats	Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms	Squamous Cell Carcinoma

keytruda unloxcyt

Rating

70/100

New

Pharmacy pays

—

Type

Active ingredient

PEMBROLIZUMAB

COSIBELIMAB-IPDL

Manufacturer

Merck Sharp Dohme

Checkpoint Therapeutics Inc

Dosage forms

Injectable

Drug class

Programmed Death Receptor-1 Blocking Antibody

—

Boxed warning

None

Treats

Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms

Squamous Cell Carcinoma

Frequently asked questions

What is the difference between Keytruda and Unloxcyt?

Keytruda contains Pembrolizumab, while Unloxcyt contains Cosibelimab-Ipdl — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.